Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Cytosorbents
CTSO
Cytosorbents
Aging Population And Rising ICU Demand Will Boost Adoption
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
15 Aug 25
Updated
21 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$10.00
90.9% undervalued
intrinsic discount
21 Aug
US$0.91
Loading
1Y
-15.5%
7D
-21.3%
Author's Valuation
US$10.0
90.9% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$10.0
90.9% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-41m
103m
2014
2017
2020
2023
2025
2026
2028
Revenue US$103.3m
Earnings US$17.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
28.55%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.62%
Calculation
US$17.43m
Earnings '28
x
69.28x
PE Ratio '28
=
US$1.21b
Market Cap '28
US$1.21b
Market Cap '28
/
94.91m
No. shares '28
=
US$12.73
Share Price '28
US$12.73
Share Price '28
Discounted to 2025 @ 8.36% p.a.
=
US$10.00
Fair Value '25